November 11, 2025 — Leads & Copy —
BOSTON and SAN DIEGO – SOPHiA GENETICS and Element Biosciences, Inc. have announced a partnership uniting sequencing and AI analytics to streamline genomic workflows and accelerate research supporting precision medicine. The announcement was made today at the Association for Molecular Pathology (AMP) Annual Meeting.
The collaboration integrates SOPHiA GENETICS’ AI-powered analytics platform, SOPHiA DDM™, with Element’s AVITI24™ 5D multiomic and AVITI™ sequencing systems. This integration delivers a seamless, end-to-end workflow for next-generation sequencing (NGS). The combined technologies will provide clinical researchers with speed, scalability, and flexibility, enabling them to turn NGS data into actionable insights within a streamlined process.
AVITI and AVITI24 users will also gain access to the full suite of SOPHiA DDM™ applications in oncology and rare disease, expanding the analytical power of their sequencing workflows.
Professor Hagay Sobol, Head of the Molecular Oncogenetics Laboratory at the Institut Paoli-Calmettes (IPC), believes that combining the Element AVITI system with the SOPHiA DDM™ Platform has the potential to transform genomic testing by delivering highly accurate results. Sobol expects that the collaboration will deliver the consistency and scalability needed for research that helps bring precision medicine to more patients, faster.
Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS, stated that integrating their universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local. Camblong added that the partnership aligns with their shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of their respective technologies.
Molly He, CEO and Co-Founder of Element Biosciences, said that pairing Element’s AVITI and AVITI24 systems with SOPHiA GENETICS’ AI analytics is a game-changer for the genomics community. He added that the collaboration redefines what’s possible in sequencing, delivering richer insights, faster results and unprecedented accessibility, breaking down barriers to enable the future of precision medicine and empower every lab to do more with their data.
SOPHiA DDM™ is a technology-agnostic analytics platform that leverages AI to compute, standardize and analyze healthcare data. SOPHiA GENETICS has been committed to ensuring compatibility across all technologies, allowing laboratories to process datasets of any size, retain full control of their data, and scale efficiently as precision medicine adoption accelerates worldwide.
Element Biosciences’ AVITI24 5D Multiomic and AVITI next generation sequencing systems are designed to make high-performance genomics accessible to all. Element empowers laboratories to scale with confidence and accelerate the research driving precision medicine worldwide with its combination of accuracy, flexibility, and cost efficiency.
To learn more about the partnership or SOPHiA GENETICS, visit booth 921 at AMP in Boston, Massachusetts from November 11 – 15 or visit SOPHiAGENETICS.com.
SOPHiA DDM™ is for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Contact support@sophiagenetics.com for product information for your country of residence.
Contact: support@sophiagenetics.com
Source: SOPHiA GENETICS
